Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Mesoblast Limited before investing.

In this article, we go over a few key elements for understanding Mesoblast Limited’s stock price such as:

• Mesoblast Limited’s current stock price and volume
• Why Mesoblast Limited’s stock price changed recently
• Upgrades and downgrades for MESO from analysts
• MESO’s stock price momentum as measured by its relative strength

About Mesoblast Limited (MESO)

Before we jump into Mesoblast Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Want to learn more about Mesoblast Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Mesoblast Limited.

Mesoblast Limited’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Mesoblast Limited’s stock price was $17.370.

Mesoblast Limited is up 8.16% from its previous closing price of $16.060.

During the last market session, Mesoblast Limited’s stock traded between $17.350 and $17.790. Currently, there are approximately 1,273.28 million shares outstanding for Mesoblast Limited.

Mesoblast Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Mesoblast Limited Stock Price History

Mesoblast Limited’s (MESO) price is currently up 4.26% so far this month.

During the month of November, Mesoblast Limited’s stock price has reached a high of $17.790 and a low of $14.100.

Over the last year, Mesoblast Limited has hit prices as high as $22.000 and as low as $9.610. Year to date, Mesoblast Limited’s stock is down 12.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Mesoblast Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were analysts who downgraded Mesoblast Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Mesoblast Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Mesoblast Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Mesoblast Limited (MESO) by visiting AAII Stock Evaluator.

Relative Price Strength of Mesoblast Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Mesoblast Limited has a weighted four-quarter relative price strength of 17.81%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Mesoblast Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Mesoblast Limited Stock Price: Bottom Line

As of November 26, 2025, Mesoblast Limited’s stock price is $17.370, which is up 8.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Mesoblast Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.